Visual summary
Hospitalization, procedures, bleeding, changes in function, and new evidence can alter the balance. A previous decision does not remove the need for review.
Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.
Diagram description
Balance the indication against bleeding and burden. Thromboembolic risk — Define the reason for anticoagulation; Bleeding risk — Prior events, medicines and dialysis context; Treatment exposure — Pharmacokinetics do not prove net benefit; Shared reassessment — Preferences, events and changing circumstances. Evidence in dialysis differs from the general population; avoid automatic extrapolation. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.
Text version
A difficult risk balance
Dialysis patients can face both stroke and substantial bleeding risk. General-population risk scores and trials do not automatically transfer to this setting.
Define the indication
Atrial fibrillation, venous thrombosis, valve disease, and access-related anticoagulation are different questions with different evidence.
Separate pharmacology from outcomes
A drug concentration or anti-Xa effect demonstrates exposure, not proven stroke prevention or net clinical benefit for a particular dialysis dose.
Share the decision
Discuss uncertain benefit, bleeding history, interactions, frailty, patient priorities, and alternatives. Dose selection must follow the indication and current prescribing framework.
Chair-side observations
Report prolonged access bleeding, bruising, falls, melena, new neurologic symptoms, and medication changes. Verify rather than independently change the anticoagulant plan.
Reassess repeatedly
Hospitalization, procedures, bleeding, changes in function, and new evidence can alter the balance. A previous decision does not remove the need for review.
